Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AR-C165395XX in Type 2 Diabetes Mellitus
NCT02367066Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2015
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AR-C165395XX in type 2 diabetes mellitus (T2DM), sponsored by AstraZeneca. Started Mar 2015; status: completed.
02
Drugs
AR-C165395XX
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02367066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02367066.